A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of REL-1017 Monotherapy for Major Depressive Disorder
Latest Information Update: 28 Mar 2024
At a glance
- Drugs Esmethadone (Primary)
- Indications Major depressive disorder
- Focus Registrational; Therapeutic Use
- Acronyms Reliance III
- Sponsors Relmada Therapeutics
- 08 Aug 2023 According to a Relmada Therapeutics media release, research and development expense for the six months ended June 30, 2023, totaled $29.6 million, compared to $55.9 million for the six months ended June 30, 2022. The decrease was primarily driven by a decrease in study costs associated with the completion of Reliance I and III in late 2022.
- 07 Dec 2022 According to a Relmada Therapeutics media release, based on the results of RELIANCE I and RELIANCE III, the company is applying several protocol and operational changes to RELIANCE II and making certain improvements to how the trial is being conducted.
- 10 Nov 2022 According to a Relmada Therapeutics media release, the company is currently further analyzing the recently announced top-line results from the trial.